Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Modafinil
Modafinil (2-benzhydrylsulfinylacetamide) is a synthetic eugeroic of the benzhydryl sulfinyl class. It is the active metabolite of adrafinil, without the euphoria or physical drive of classical stimulants.[1][2] It blocks dopamine reuptake in wake-promoting brain regions, sharpening alertness without a stimulant rush.[3]
Modafinil (2-benzhydrylsulfinylacetamide) is a synthetic eugeroic of the benzhydryl sulfinyl class. It is the active metabolite of adrafinil, distinguished from classical stimulants by the absence of euphoria or locomotor drive.[1][2] Modafinil is a DAT inhibitor, producing its effects by blocking dopamine reuptake in wake-promoting brain regions.[3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
French researchers identified modafinil in the 1970s as the active form of adrafinil, and neurophysiologist Michel Jouvet began giving it to narcolepsy patients by 1983.[4] The French military deployed it in the 1991 Gulf War, and the FDA approved it as Provigil for narcolepsy in 1998.[5] It is now one of the most widely prescribed wake-promoting drugs globally, used both clinically and off-label.
Subjective effects include wakefulness promotion, sharpened focus, increased motivation, appetite suppression, and mild mental clarity. The experience is defined by subtraction — sedation recedes and the cognitive foreground sharpens, without a rush, mood lift, or somatic buzz. Headache, insomnia, nausea, and anxiety are common unwanted effects.
Physical dependence is very low, and no lethal dose has been established in humans.[6] The primary serious risk is a rare but potentially fatal blistering skin reaction that can appear within the first weeks of use, cannot be predicted, and prompted the FDA to block pediatric approval.[7] Decades of prescription data yield a well-characterized safety profile, though interaction data for recreational drug combinations remain largely uncharacterized.
History[edit]
Discovery
French researchers identified adrafinil in 1974 as a compound that increased wakefulness in mice without peripheral stimulant effects.[4] Modafinil emerged as its primary active metabolite. Neurophysiologist Michel Jouvet began giving it directly to narcolepsy patients in 1983, achieving marked reductions in daytime sedation.[4]
Clinical Adoption
France registered modafinil in 1992 as Modiodal, and the French military had already deployed it to sustain personnel during the 1991 Gulf War — an early proof of concept.[4] In the United States, Cephalon Inc. secured FDA approval under the name Provigil for narcolepsy in 1998, with indications extended to shift work sleep disorder and sleep apnea in 2003.[5][6]
Modern Era
In 2007, the FDA approved armodafinil (Nuvigil) — the isolated longer-acting component of modafinil — offering a simpler pharmacokinetic profile.[8] Modafinil is now among the most widely prescribed wake-promoting agents globally, with research spanning cognitive enhancement,[9] mood disorders,[10] and military aviation fatigue.[11][12]
In online nootropic communities, modafinil has become the archetypal "smart drug," discussed alongside caffeine and racetams as a cognitive performance tool. Its reputation centers on productivity rather than recreation — a framing that distinguishes it from most controlled substances in popular discourse.
Chemistry[edit]
Structural Class
Modafinil belongs to the benzhydryl sulfinyl family — defined by a diphenylmethyl group bonded to a sulfinyl (S=O) moiety and an acetamide side chain.[1] Its molecular formula is C₁₅H₁₅NO₂S (molecular weight 273.4 g/mol).[7] It is the active metabolite of the prodrug adrafinil, which undergoes conversion to modafinil in the liver.[4]
This scaffold is structurally distinct from amphetamine and methylphenidate.[1] That structural difference explains why modafinil blocks dopamine reuptake without triggering dopamine release — producing wakefulness without the rush of classical stimulants. The drug exists as a racemic mixture; armodafinil is its isolated longer-acting form, with a half-life roughly three times that of the other component.[8]
Pharmacology[edit]
Mechanism of Action
Modafinil blocks dopamine reuptake in wake-promoting brain regions, raising dopamine levels and sustaining alertness.[1][3] Unlike cocaine or amphetamine, it does not cause dopamine release — it only slows its clearance.[2][1] This produces wakefulness without a rush and substantially lowers abuse potential. Mice without the DAT are completely unresponsive to the compound.[13]
Secondary Neurochemical Effects
Modafinil's other neurochemical effects are downstream consequences of raising dopamine.[1][6] Norepinephrine rises in the prefrontal cortex, and wake-promoting neurons that signal via histamine become more active.[14] The net result is a shift toward greater excitation across multiple systems.[15][14]
Pharmacokinetics
Taken orally, modafinil reaches peak blood levels in 2–4 hours and has an overall half-life of 12–15 hours.[16][8] Steady-state concentrations are reached within 2–4 days of repeated dosing; metabolism occurs in the liver, with less than 10% excreted unchanged.[16] Critically, modafinil speeds up liver enzymes that break down hormonal contraceptives — reducing their effectiveness — and slows enzymes that clear certain other drugs, raising their levels.[16][6]
Neuroscience[edit]
Where It Acts
Modafinil raises dopamine in the striatum — including the nucleus accumbens, a hub of motivation and reward — at therapeutic doses.[3][17] It also makes the prefrontal cortex more efficient during demanding tasks: equivalent or better cognitive performance with less neural effort.[18]
Why It Matters
Modafinil raises dopamine in the reward circuit without producing strong euphoria.[2] This distinction — amplifying motivation without the pleasure rush — explains why it enhances task engagement without the addictive pull of classical stimulants. With chronic use, dopamine receptor balance shifts in reward pathways, providing the molecular basis for the tolerance seen in long-term patients.[19][20]
Several puzzles remain. The gap between modafinil's low laboratory affinity for the DAT and its high brain occupancy at therapeutic doses is not fully explained.[2] Mice without orexin respond more strongly to modafinil than normal mice[21] — implying compensatory changes that are not yet characterized. Whether tolerance can be prevented or reversed is unknown, though drug holidays with pitolisant bridging have shown clinical promise.[20]
Subjective Effects[edit]
Modafinil's defining quality is what it removes. Sleepiness recedes, the pull toward distraction fades, and attention settles on the task at hand — without urgency, rush, or mood lift. There is no perceptible onset, no euphoria. Sleep status is the strongest determinant: sleep deprivation amplifies the effect dramatically, while well-rested users may notice only subtle shifts.
Compared to amphetamine, modafinil produces less cardiovascular activation, weaker appetite suppression, and minimal mood elevation. Compared to caffeine, effects are longer-lasting and more cognitively specific, with headache as the dominant side effect rather than anxiety or tremor. The experience is subtler than either — closer to the absence of tiredness than the presence of energy.
Modafinil emerged from pharmaceutical research at Laboratoire Louis Lafon in France during the 1970s, with neurophysiologist Michel Jouvet driving its clinical development for narcolepsy.[4] FDA approval followed in 1998, with indications extended to shift work sleep disorder and obstructive sleep apnea in 2003.[5] It is now one of the most widely prescribed wake-promoting agents globally, with off-label investigation spanning cognitive enhancement,[6] adjunctive psychiatric treatment,[7] and military fatigue countermeasures.[8]
Subjective effects include wakefulness promotion, cognitive enhancement, increased motivation, and appetite suppression. The experience is defined by subtraction — sedation recedes and the cognitive foreground sharpens without a perceptible stimulant rush, mood elevation, or somatic urgency. Headache, insomnia, nausea, and anxiety are common unsought effects.
Modafinil produces very low physical dependence and has no established lethal dose in humans.[9] The primary acute risk is rare but potentially fatal skin hypersensitivity — Stevens-Johnson syndrome — which is unpredictable in onset and prompted the FDA to reject pediatric approval;[10] chronic use produces tolerance via dopamine receptor changes.[11][12] Decades of clinical data and widespread prescription use underpin a well-characterized safety profile, though interaction data for recreational drug combinations remain largely uncharacterized.
History[edit]
Discovery
Research at Laboratoire Louis Lafon in France identified adrafinil in 1974, a benzhydryl sulfinyl compound that increased wakefulness in mice without peripheral stimulant effects.[4] Pharmacokinetic analysis revealed modafinil as adrafinil's primary active metabolite, and it was synthesized independently. Neurophysiologist Michel Jouvet at the University of Lyon began administering modafinil directly to narcolepsy patients in 1983, achieving marked reductions in daytime sedation — results that eventually persuaded Lafon to pursue formal clinical development.[4]
Clinical Adoption
Modafinil's first major operational deployment came during the 1991 Gulf War, when the French military administered it to personnel to sustain operations — a significant proof of concept.[4] France registered the compound in 1992 under the trade name Modiodal.[4] In the United States, Cephalon Inc. secured FDA approval under the trade name Provigil for narcolepsy in 1998,[5][9] with indications extended to shift work sleep disorder and obstructive sleep apnea in 2003.[5]
Modern Era
In 2007, the FDA approved armodafinil (the isolated R-enantiomer) under the trade name Nuvigil, offering a simplified pharmacokinetic profile with only the longer-acting enantiomer.[13] Modafinil has since become one of the most widely prescribed wake-promoting agents globally, with off-label research spanning cognitive enhancement,[6] adjunctive psychiatric treatment,[7] neurological fatigue,[14] and military aviation fatigue countermeasures.[15][8] Military use has expanded from French forces to regulated programs across multiple nations.[15]
The name "modafinil" derives from its pharmaceutical identity as a modified adrafinil metabolite. In online nootropic communities, modafinil has become the archetypal "smart drug," frequently discussed alongside caffeine and racetams as a cognitive performance tool. Its reputation centers on productivity enhancement rather than recreation — a framing that distinguishes it from most controlled substances in popular discourse.
Chemistry[edit]
Structural Class
Modafinil belongs to the benzhydryl sulfinyl family, characterized by a diphenylmethyl (benzhydryl) group linked to a sulfinyl moiety. The parent compound adrafinil is a prodrug that undergoes liver metabolism to yield modafinil as its primary active metabolite.[4]
The benzhydryl sulfinyl scaffold is structurally distinct from amphetamine, methylphenidate, and other classical stimulants. This divergence underlies modafinil's atypical pharmacological profile — dopamine reuptake inhibitor without robust dopamine release or locomotor activation.[1]
Molecular Structure
| Molecular formula | C₁₅H₁₅NO₂S |
| Molecular weight | 273.4 g/mol |
The molecule consists of two phenyl rings attached to a central carbon (the benzhydryl center), bonded to a sulfinyl group (S=O). The sulfinyl moiety connects to an acetamide side chain. The sulfur atom bears an oxygen and constitutes the chirality center responsible for the compound's stereoisomerism.[1]
Stereochemistry
Modafinil is a racemic compound — an equal mixture of R- and S-enantiomers. The chiral center resides at the sulfur atom. The R-enantiomer (armodafinil) is the pharmacologically dominant form: it is eliminated approximately three times more slowly than the S-enantiomer (half-life ~15 hours vs ~4 hours), resulting in sustained plasma concentrations and prolonged activity.[13]
Physical Properties
Modafinil presents as a white to off-white crystalline powder. It is practically insoluble in water and sparingly soluble in methanol and acetone.[10]
Pharmacology[edit]
Mechanism of Action
Modafinil is an atypical dopamine transporter (DAT) inhibitor. It blocks the reuptake of dopamine, raising extracellular dopamine concentrations in wake-promoting brain regions.[1][3]
The necessity of DAT for modafinil's effects was established definitively: DAT knockout mice are completely unresponsive to the compound, while normal littermates show robust wakefulness.[16] Brain imaging in humans confirms that therapeutic doses block DAT in the striatum, producing measurable dopamine increases.[3][17] Both D1 and D2 dopamine receptors are required for the arousal response — blocking either one abolishes modafinil-induced wakefulness.[18]
Unlike classical stimulants such as cocaine or amphetamine, modafinil binds DAT with low affinity and does not cause dopamine release or transporter reversal.[2][1] This accounts for its weaker reinforcing properties and reduced abuse potential.
Secondary Neurochemical Effects
Modafinil has minimal direct binding at norepinephrine, serotonin, or histamine transporters.[9][1] Its effects on other neurotransmitter systems are indirect, driven downstream by dopaminergic activation.
These secondary effects include elevated norepinephrine in the prefrontal cortex and hypothalamus, with measurable increases in plasma and urinary catecholamines at 400 mg.[19] Serotonin levels rise indirectly,[6] and histamine-producing neurons in the hypothalamus are activated, contributing to wake promotion.[20] The glutamate-GABA balance shifts toward greater excitation.[21][20]
Modafinil also activates orexin-containing neurons,[22] though orexin is not required for its wake-promoting effects — mice lacking orexin actually respond more strongly to modafinil than normal mice.[23]
Pharmacokinetics
Modafinil is administered orally. Peak blood levels occur 2–4 hours after ingestion.[24] The overall half-life is 12–15 hours for the racemic mixture, with the R-enantiomer lasting approximately 15 hours and the S-enantiomer approximately 4 hours.[13][24]
The drug shows dose-independent pharmacokinetics across 200–600 mg/day.[24] Steady-state concentrations are reached within 2–4 days of repeated dosing. Metabolism occurs primarily in the liver via amide hydrolysis to an inactive metabolite, with less than 10% excreted unchanged.[24]
Modafinil's enzyme interactions are clinically significant: it induces CYP3A4 (reducing the effectiveness of hormonal contraceptives and other medications metabolized by this pathway), inhibits CYP2C19, and suppresses CYP2C9.[24][9]
Neuroscience[edit]
Where It Acts
Modafinil's primary neural action is potentiation of dopamine signaling in the striatum, including the nucleus accumbens — a key node in reward processing.[3] Therapeutic doses produce high DAT occupancy in these regions,[17] elevating dopamine in both reward-related and executive circuits.
Functional brain imaging shows that modafinil increases the efficiency of prefrontal cortex activation during working memory tasks: equivalent or superior performance is achieved with reduced neural activity, suggesting more efficient processing rather than brute-force cortical recruitment.[25] The compound also reduces amygdala reactivity to threatening stimuli,[25] consistent with the reduced anxiety some users report at lower doses.
Why It Matters
Modafinil's distinctive profile — raising dopamine in the nucleus accumbens without producing strong euphoria — illustrates the neuroscience of wanting versus liking. Its atypical binding mode (stabilizing an outward-facing DAT conformation rather than reversing transport) produces a qualitatively different dopamine signal than cocaine or amphetamine.[2] This may explain why modafinil enhances motivation and task engagement without the hedonic rush of classical stimulants.
Chronic use drives neuroplastic changes: differential expression of D2 receptor subtypes in the brain's reward pathways[12] provides a molecular basis for the tolerance documented in long-term patients.[11]
Several puzzles remain unresolved. The gap between modafinil's low laboratory DAT affinity and its high brain occupancy at therapeutic doses is not fully explained — structural studies suggest it stabilizes a distinct transporter conformation,[2] but quantitative modeling is incomplete.
Subjective Effects[edit]
Modafinil's experiential character is defined as much by what it does not produce as by what it does. There is no perceptible euphoric onset, no locomotor urgency, no sympathomimetic buzz. Sleepiness recedes and the cognitive foreground sharpens — attention narrows onto tasks, the drive to disengage fades. Sleep status is the strongest modulator: sleep-deprived users experience dramatic benefits, while well-rested individuals may notice only subtle shifts in focus and stamina.
Compared to amphetamine, modafinil produces less cardiovascular activation, weaker appetite suppression, and minimal mood elevation. Compared to caffeine, effects are longer-lasting, more cognitively specific, and carry a different side-effect profile dominated by headache rather than anxiety or tremor.
Effect Grid
At common doses (100–200 mg oral), modafinil produces its characteristic eugeroic and cognitive enhancement profile. Wakefulness promotion is pronounced — sleepiness is strongly suppressed, and sustained attention capacity increases markedly. Focus enhancement and motivation enhancement are the dominant cognitive effects; executive function improves for planning, decision-making, and complex problem-solving tasks.
Appetite suppression becomes reliable. Heart rate may increase modestly (3–5 bpm). Headache, the most common adverse effect, occurs in up to 34% of users at this range. Mild nausea affects approximately 11%. Some users report a subtle sense of emotional flattening or reduced social spontaneity.
Sleep is significantly delayed — administration after midday reliably disrupts sleep onset. Effects persist 5–8 hours subjectively, with residual wakefulness extending further due to the 12–15 hour half-life.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Dehydration sensation · Headache · Dry mouth · Pupil dilation · Nausea · Heart rate perception changes · Restlessness · Diarrhea · Dizziness
Nausea · Heart rate perception changes · Restlessness · Diarrhea · Dizziness
Memory enhancement · Thought acceleration
Timeline
First perceptible effects emerge as a subtle increase in alertness and a fading of background sleepiness. The transition is gradual — modafinil does not produce an abrupt "kick" like amphetamines.
Wakefulness solidifies and focus sharpens progressively. Appetite begins to diminish. A gentle sense of cognitive clarity builds without overt physical stimulation.
Maximum wakefulness and cognitive enhancement. Executive function, sustained attention, and motivation reach their highest levels. Appetite suppression is most pronounced.
Effects remain stable but begin to feel less prominent as adaptation occurs over the session. Wakefulness persists without the sense of active enhancement. Some users experience mild headache or fatigue beginning to reassert.
Gradual return toward baseline over several hours. Sleepiness slowly re-emerges. Appetite returns.
Residual wakefulness and mild cognitive sharpness may persist for 6–12 hours beyond the subjective peak, consistent with the 12–15 hour elimination half-life. Sleep architecture may be altered on the night following administration.
⚠ Do not drive or operate heavy machinery if experiencing residual fatigue or rebound sleepiness, particularly after sleep disruption from late dosing.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- slow
- Tolerance reset
- —
- Physical
- None
- Psychological
- Low
- Compulsive redosing
- Negligible
- Dose escalation
- Low
- Cross-tol.
- armodafinil · adrafinil
Toxicity
Acute Toxicity
No lethal dose has been established in humans, and about 80% of overdose cases resolve without medical intervention.[6] Overdose symptoms include rapid heart rate, agitation, insomnia, dizziness, and anxiety. No specific antidote exists.
Common side effects at therapeutic doses: headache (up to 34%), nausea (~11%), decreased appetite (≤10%), insomnia (~5%), anxiety (~5–10%), dizziness (~5%), and raised blood pressure (~3–4%).[6]
Cardiovascular Effects
At 400 mg, modafinil raises resting heart rate by approximately 9 bpm and blood pressure by approximately 7/5 mmHg.[22] Rare post-marketing reports include irregular heartbeats and reduced blood flow to the heart.[6]
Skin Reactions
The most serious safety signal is a rare but potentially fatal skin reaction. Blistering, peeling rashes — including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS — have been reported in post-marketing surveillance, typically appearing within 1–5 weeks of starting.[7]
Children show a higher rate of serious skin reactions than adults.[5] This contributed directly to the FDA's rejection of pediatric ADHD approval.[23]
Discontinue modafinil at the first appearance of any rash. It is not possible to reliably predict which rashes will progress to SJS or TEN.[7]
Other Allergic Reactions
Swelling of the face or throat (angioedema) has been reported and requires immediate discontinuation.[7] Multi-organ hypersensitivity reactions have a median onset of 13 days from starting; at least one death has been reported in post-marketing experience.[7]
Pregnancy
Modafinil is contraindicated in pregnancy.[6][7] Post-marketing data associate it with congenital heart defects and other birth abnormalities. Because modafinil reduces the effectiveness of hormonal contraceptives, alternative or additional contraception is required during treatment and for one month after stopping.[16][7]
Psychological Risks
Post-marketing reports include psychosis, hallucinations, mania, and suicidal thinking at therapeutic doses.[6][7] Pre-existing psychotic or bipolar disorders represent contraindications or require extreme caution.[7] The prevalence of these effects at therapeutic doses is low but has not been precisely quantified.
Tolerance & Dependence
Tolerance to wakefulness effects develops with long-term use, requiring dose increases over time.[20] Dopamine receptor expression in the brain's reward pathways changes, providing the molecular basis for this tolerance.[19] Drug holidays with pitolisant bridging have been described as an effective management strategy.[20]
Physical dependence has not been demonstrated in controlled studies, and a 14-day cessation study found no withdrawal.[6] Psychological dependence is rare; reinforcement are consistently weaker than those of cocaine or amphetamine.[15][24] DEA Schedule IV placement reflects a non-zero but low abuse potential; people with a history of substance use disorders may face elevated risk.[25][3]
Drug Interactions
Modafinil's enzyme profile creates significant drug interactions.[16] It accelerates the breakdown of hormonal contraceptives, reducing their effectiveness — alternative contraception is required during therapy and for one month after stopping.[16][7] It causes warfarin and phenytoin to accumulate (raising bleeding risk and seizure drug levels), and reduces levels of cyclosporine, triazolam, and clozapine.[16]
Combining modafinil with MDMA adds cardiovascular strain from both sides — modafinil raises heart rate and blood pressure[22] while MDMA floods the brain with monoamines; no published study of combined use exists.[26]inferred The tramadol interaction is bidirectional and may raise seizure and cardiovascular risk.[16][6]safety citation needed No published data exist for modafinil combined with alcohol.
Contraindications
8 knownAbsolute contraindications:
- Known hypersensitivity to modafinil or armodafinil (risk of angioedema, SJS/TEN, DRESS, multi-organ reactions)[7]
- Pregnancy (associated with birth defects)[6][7]
Relative contraindications:
- Pre-existing heart conditions, uncontrolled high blood pressure, or recent heart attack — modafinil raises heart rate, blood pressure, and stress hormones[22][6]
- History of psychosis, mania, or bipolar disorder — risk of psychiatric destabilization[6]
- Severe liver impairment — reduced elimination, maximum dose 100 mg/day[6]
- Kidney disease — accumulation of inactive metabolite[6]
- Children — not FDA-approved; elevated risk of serious skin reactions[23]
In overdose: monitor heart rhythm, blood pressure, and mental status. Benzodiazepines may be given for agitation. No specific antidote exists. Approximately 80% of cases resolve without medical intervention.[6]
Harm Reduction[edit]
Forms & Identification
Modafinil circulates primarily as pharmaceutical tablets (100 mg and 200 mg). Tablets from licensed manufacturers are reliable in dose and identity. Counterfeit tablets — especially from online sources without a prescription — may contain incorrect doses, no active ingredient, or substituted compounds.
Reagent testing cannot confirm modafinil specifically but can help rule out substitution with amphetamines or other stimulants. Powder forms introduce significant dosing imprecision without an analytical balance.
Guidelines
- Take modafinil in the morning or early afternoon — dosing after midday commonly causes insomnia
- Eat regular meals on a schedule; do not rely on appetite signals while the drug is active
- Drink water throughout the day — headache, the most common side effect, is partly dehydration-mediated
- Do not escalate dose if effects feel subtle; modafinil's cognitive benefits are often more apparent in retrospect than in real time
- If using hormonal contraceptives, use additional contraception during modafinil use and for one month after stopping
- Stop immediately at the first sign of any rash and seek medical evaluation
- Avoid combining with other stimulants (caffeine excepted at moderate doses) until cardiovascular tolerance is understood
Set & Setting
Modafinil is used in functional contexts — work, study, or sustained wakefulness — rather than recreational ones. Take it in the morning or early afternoon to avoid interference with nighttime sleep. Hydration and regular meals are easy to neglect under its appetite-suppressing effects.
First-time users should start at the lower end of the therapeutic range and avoid combining with other stimulants until individual response is understood. Cognitive effects are subtle in well-rested individuals; expectations calibrated to amphetamine-like stimulation will be disappointed.
Aftercare & integration. Modafinil's primary aftercare concern is sleep. The long half-life (12–15 hours) means a morning dose can still suppress sleep architecture that night, even when the user feels ready for bed. Prioritize a full night of unmedicated sleep after each use day.
If modafinil was used to push through sleep deprivation, recovery sleep should come first once the task is done — not another dose. Chronic sleep debt compounds regardless of wakefulness-promoting agents. Eat a substantial evening meal; appetite suppression during the day often causes caloric deficit.
Recovery & Support
Modafinil dependence is uncommon, but habitual daily use can develop — particularly among people using it to compensate for chronic sleep deprivation or unsustainable work schedules. The pattern is functional: the substance becomes embedded in productivity routines rather than sought for euphoria.
If use has become daily and dose escalation has occurred, a gradual taper is preferable to abrupt cessation. The underlying sleep or schedule problem needs addressing — modafinil masks fatigue without resolving it. A physician can evaluate whether continued use is clinically appropriate and discuss alternatives including sleep hygiene, schedule adjustment, or pitolisant bridging for tolerance management.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Modafinil overdoses are rarely life-threatening, but certain symptoms require immediate medical attention.
Recognizing an emergency:
- Chest pain, pounding or irregular heartbeat
- Severe agitation, confusion, or psychotic symptoms (hallucinations, paranoid thinking)
- Skin rash developing blisters, peeling, or spreading rapidly
- Swelling of the face, lips, or throat (difficulty breathing or swallowing)
- Seizure or loss of consciousness
Immediate steps:
- 1. Call emergency services if any of the above symptoms are present
- 2. Keep the person calm and in a cool, quiet environment
- 3. Do not induce vomiting
- 4. If the person is unconscious, place them in the recovery position
- 5. Monitor breathing and heart rate until help arrives
What to tell the dispatcher: Name the substance (modafinil), the dose taken if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
As of April 2026, modafinil is a prescription-controlled medication in most major jurisdictions. It is not internationally scheduled under the Convention on Psychotropic Substances (1971),citation needed so regulation is handled by individual nations.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | DEA placement effective January 27, 1999. FDA-approved for narcolepsy (1998), SWSD and OSA adjunct (2003). Prescription required; refill limitations apply[25][5] |
| United Kingdom | Prescription-Only Medicine (POM) | Regulated under the Medicines Act 1968. Not listed under the Misuse of Drugs Act 1971 — not a controlled drug. Legal to possess with valid prescription; supply without prescription is illegalcitation needed |
| France | Prescription medication (Modiodal) | First jurisdiction to approve modafinil clinically; registered 1992[4] |
| Australia | Schedule 4 (Prescription Only) | Regulated under the Therapeutic Goods Act. Importation without valid Australian prescription is illegalcitation needed |
| Canada | Schedule I (Food and Drugs Act) | Prescription requiredcitation needed |
| European Union | Prescription required (varies by member state) | Marketed as Modiodal in France and other countries; specific regulatory status varies by member state |
Legal status changes over time and varies by jurisdiction. This table reflects status as of April 2026 and is not legal advice.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- slow
- Tolerance reset
- —
- Physical
- None
- Psychological
- Low
- Compulsive redosing
- Negligible
- Dose escalation
- Low
- Cross-tol.
- armodafinil · adrafinil
Toxicity
Acute Toxicity
Modafinil has a wide safety margin. No lethal dose has been established in humans.[9] Most overdose cases resolve with supportive care; approximately 20% require medical intervention. The most common overdose symptoms are rapid heart rate, insomnia, agitation, dizziness, and anxiety.[9] No specific antidote exists.
Common side effects at therapeutic doses include headache (up to 34%), nausea (~11%), decreased appetite (≤10%), insomnia (~5%), anxiety (~5–10%), dizziness (~5%), and raised blood pressure (~3–4%).[9]
Cardiovascular Effects
At 400 mg, modafinil increases resting heart rate by approximately 9.2 bpm, systolic blood pressure by 7.3 mmHg, and diastolic blood pressure by 5.3 mmHg.[19] Rare post-marketing reports include irregular heartbeats and reduced blood flow to the heart.[9]
Skin Reactions
The most serious safety signal involves Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms). These rare but potentially fatal skin reactions have been reported in both adults and children through post-marketing surveillance.[10] Onset typically occurs within 1–5 weeks of starting the medication.
Children and adolescents show a higher rate of serious skin reactions than adults,[5] a finding that contributed to the FDA's rejection of pediatric ADHD approval.[26]
Discontinue modafinil at the first appearance of any rash. It is not possible to reliably predict which rashes will progress to SJS or TEN.[10]
Other Allergic Reactions
Swelling of the face or throat (angioedema) has been reported; immediate discontinuation is advised.[10] Multi-organ hypersensitivity reactions have a median onset of 13 days from initiation, with at least one death reported in post-marketing experience.[10]
Pregnancy
Modafinil is contraindicated in pregnancy. Post-marketing data associate exposure with congenital heart defects and other birth abnormalities.[9][10] Because modafinil reduces the effectiveness of hormonal contraceptives, alternative or additional contraception is required during treatment and for one month after stopping.[24][10]
Psychological Risks
Post-marketing surveillance has identified psychosis, hallucinations, mania, and suicidal thinking occurring at therapeutic doses.[9][10] Pre-existing psychotic or bipolar disorders represent contraindications or require extreme caution.[10]
The prevalence of psychiatric side effects at therapeutic doses is low but has not been precisely quantified in large-scale studies.
Tolerance & Dependence
Tolerance to modafinil's wake-promoting effects develops with long-term use, manifesting as reduced efficacy requiring dose increases.[11] The underlying mechanism involves changes in D2 dopamine receptor expression in the brain's reward pathways.[12] Drug holidays supported by pitolisant bridging have been described as an effective management strategy.[11]
Physical dependence has not been demonstrated in controlled studies. A 14-day cessation study showed no withdrawal.[9] Psychological dependence is very rare compared to classical stimulants.[21]
The dependence risk is very low but non-zero. Brain imaging confirmed that modafinil increases dopamine in the nucleus accumbens,[3] prompting DEA Schedule IV placement.[27] People with a history of substance use disorders may face elevated risk.[3] Reinforcing effects are consistently weaker than those of cocaine or amphetamine.[28]
Drug Interactions
Modafinil's liver enzyme profile creates a complex interaction landscape.[24]
The most clinically significant interaction involves hormonal contraceptives: modafinil reduces their effectiveness by accelerating their breakdown. Alternative or additional contraception is required during therapy and for one month after stopping.[24][10]
Warfarin requires close monitoring of blood clotting, as modafinil can cause warfarin to accumulate and increase bleeding risk.[24] Phenytoin may accumulate due to enzyme inhibition.[24] Cyclosporine, triazolam, and clozapine levels may be reduced.[24]
Strong CYP3A4 inhibitors (ketoconazole, ritonavir) may increase modafinil exposure, while CYP3A4 inducers (rifampin) may reduce it.[9]
The tramadol interaction involves bidirectional risk: modafinil may accelerate tramadol clearance during co-administration, and stopping modafinil may increase tramadol exposure as enzyme effects fade. Combined stimulant load may increase seizure and cardiovascular risk.[24][9]safety citation needed
The MDMA interaction carries additive cardiovascular strain — modafinil increases heart rate, blood pressure, and stress hormones,[19] and MDMA independently produces massive monoamine release. No published study of combined use exists; risk assessment is mechanism-based.[29]inferred
No published interaction data exist for modafinil combined with alcohol.
Contraindications
8 knownAbsolute contraindications:
- Known hypersensitivity to modafinil or armodafinil (risk of angioedema, SJS/TEN, DRESS, multi-organ reactions)[10]
- Pregnancy (associated with birth defects)[9][10]
Relative contraindications:
- Pre-existing heart conditions, uncontrolled high blood pressure, or recent heart attack — modafinil raises heart rate, blood pressure, and stress hormones[19][9]
- History of psychosis, mania, or bipolar disorder — risk of psychiatric destabilization[9]
- Severe liver impairment — reduced elimination, maximum dose 100 mg/day[9]
- Kidney disease — accumulation of inactive metabolite[9]
- Children — not FDA-approved; elevated risk of serious skin reactions[26]
In overdose: monitor heart rhythm, blood pressure, and mental status. Benzodiazepines may be given for agitation. No specific antidote exists. Approximately 80% of cases resolve without medical intervention.[9]
Harm Reduction[edit]
Forms & Identification
Modafinil circulates primarily as pharmaceutical tablets (100 mg and 200 mg), though unregulated online sources sell loose tablets and bulk powder of uncertain provenance. Pharmaceutical tablets from licensed manufacturers are generally reliable in dose and identity, but counterfeit tablets — especially those purchased online without a prescription — may contain incorrect doses, no active ingredient, or substituted compounds.
Reagent testing has limited utility for confirming modafinil specifically, but can help rule out substitution with amphetamines or other stimulants. If sourcing outside a pharmacy, testing is the minimum precaution. Powder forms introduce significant dosing imprecision without an analytical balance.
Guidelines
- Take modafinil in the morning or early afternoon — dosing after midday commonly causes insomnia
- Eat regular meals on a schedule; do not rely on appetite signals while the drug is active
- Drink water throughout the day — headache, the most common side effect, is partly dehydration-mediated
- Do not escalate dose if effects feel subtle; modafinil's cognitive benefits are often more apparent in retrospect than in real time
- If using hormonal contraceptives, use additional contraception during modafinil use and for one month after stopping
- Stop immediately at the first sign of any rash and seek medical evaluation
- Avoid combining with other stimulants (caffeine excepted at moderate doses) until cardiovascular tolerance is understood
Set & Setting
Modafinil is typically used in functional contexts — work, study, or sustained wakefulness — rather than recreational ones. The most productive approach involves taking it early in the day (morning or early afternoon) to avoid interference with nighttime sleep. Hydration and regular meals are easy to neglect under modafinil's appetite-suppressing effects.
First-time users should start at the lower end of the therapeutic range and avoid combining with other stimulants until individual response is understood. The cognitive effects are subtle in well-rested individuals; expectations calibrated to amphetamine-like stimulation will be disappointed.
Aftercare & integration. Modafinil's primary aftercare concern is sleep recovery. The long half-life (12–15 hours) means that a morning dose can still suppress sleep architecture that night, even when the user feels ready for bed. Prioritize a full night of unmedicated sleep after each use day.
If modafinil was used to sustain a period of sleep deprivation, recovery sleep should be the first priority once the task is complete — not another dose. Chronic sleep debt compounds regardless of wakefulness-promoting agents. Eat a substantial meal in the evening, as appetite suppression during the day often leads to caloric deficit.
Recovery & Support
Modafinil dependence is uncommon, but habitual use can develop — particularly among people who rely on it to compensate for chronic sleep deprivation or unsustainable work schedules. The pattern is functional rather than recreational: the substance becomes embedded in productivity routines rather than sought for euphoria.
If modafinil use has become daily and dose escalation has occurred, a gradual taper is preferable to abrupt cessation. Addressing the underlying sleep or schedule problem is essential — modafinil masks fatigue without resolving it. A physician can help evaluate whether continued use is clinically appropriate and discuss alternatives including sleep hygiene, schedule adjustment, or pitolisant bridging for tolerance management.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Modafinil overdoses are rarely life-threatening, but certain symptoms require immediate medical attention.
Recognizing an emergency:
- Chest pain, pounding or irregular heartbeat
- Severe agitation, confusion, or psychotic symptoms (hallucinations, paranoid thinking)
- Skin rash developing blisters, peeling, or spreading rapidly
- Swelling of the face, lips, or throat (difficulty breathing or swallowing)
- Seizure or loss of consciousness
Immediate steps:
- 1. Call emergency services if any of the above symptoms are present
- 2. Keep the person calm and in a cool, quiet environment
- 3. Do not induce vomiting
- 4. If the person is unconscious, place them in the recovery position
- 5. Monitor breathing and heart rate until help arrives
What to tell the dispatcher: Name the substance (modafinil), the dose taken if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
As of April 2026, modafinil is a prescription-controlled medication in most major jurisdictions. It is not listed on the International Narcotics Control Board (INCB) schedules under the Convention on Psychotropic Substances (1971),citation needed meaning international scheduling requirements do not apply. Individual nations regulate modafinil through domestic pharmaceutical or controlled substances legislation.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | DEA placement effective January 27, 1999. FDA-approved for narcolepsy (1998), SWSD and OSA adjunct (2003). Prescription required; refill limitations apply[27][5] |
| United Kingdom | Prescription-Only Medicine (POM) | Regulated under the Medicines Act 1968. Not listed under the Misuse of Drugs Act 1971 — not a controlled drug. Legal to possess with valid prescription; supply without prescription is illegalcitation needed |
| France | Prescription medication (Modiodal) | First jurisdiction to approve modafinil clinically; registered 1992[4] |
| Australia | Schedule 4 (Prescription Only) | Regulated under the Therapeutic Goods Act. Importation without valid Australian prescription is illegalcitation needed |
| Canada | Schedule I (Food and Drugs Act) | Prescription requiredcitation needed |
| European Union | Prescription required (varies by member state) | Marketed as Modiodal in France and other countries; specific regulatory status varies by member state |
Frequently asked questions
What is Modafinil?
Modafinil is a synthetic eugeroic and atypical stimulant of the benzhydryl sulfinyl class, approved for narcolepsy and wakefulness disorders. It acts primarily as a low-affinity dopamine transporter inhibitor, first developed in France in the 1970s and FDA-approved in 1998.
How long does Modafinil last?
Total duration by route of administration — Oral: 5 – 10 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Modafinil?
Psychedex publishes a dosage table for Modafinil on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Modafinil?
The highest-severity documented interactions for Modafinil: Ibogaine (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Anticholinergics (Dangerous), Antipsychotics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Modafinil addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Modafinil: tolerance builds slow; cross-tolerance develops with armodafinil, adrafinil. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcdLee KH, Camacho-Hernandez GA, Newman AH, Shi L (2024) The Structural Basis of the Activity Cliff in Modafinil-Based Dopamine Transporter Inhibitors. — Biomolecules doi:10.3390/biom14060713
- [3] ^abcdVolkow ND, Fowler JS, Logan J, et al. (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. — JAMA doi:10.1001/jama.2009.351
- [4]
- [5] ^abcdKumar R (2008) Approved and investigational uses of modafinil: an evidence-based review. — Drugs PMID:18729534
- [6]
references
- [1]
- [2] ^abcdLee KH, Camacho-Hernandez GA, Newman AH, Shi L (2024) The Structural Basis of the Activity Cliff in Modafinil-Based Dopamine Transporter Inhibitors. — Biomolecules doi:10.3390/biom14060713
- [3]
- [4]
- [5]
- [6] ^abcBattleday RM, Brem AK (2015) Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. — European neuropsychopharmacology doi:10.1016/j.euroneuro.2015.07.028